Compass Therapeutics (NASDAQ:CMPX) Given Buy Rating at D. Boral Capital

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They presently have a $32.00 price objective on the stock.

Other equities analysts also recently issued research reports about the company. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $5.00 to $4.00 in a report on Friday, November 15th. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Monday, September 16th. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Monday, November 11th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Compass Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $11.80.

Compass Therapeutics Trading Down 9.5 %

NASDAQ CMPX opened at $1.43 on Wednesday. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.34. The firm’s fifty day simple moving average is $1.56 and its 200-day simple moving average is $1.44. The company has a market capitalization of $196.75 million, a PE ratio of -3.86 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. As a group, analysts predict that Compass Therapeutics will post -0.35 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rovin Capital UT ADV bought a new stake in shares of Compass Therapeutics during the 3rd quarter worth $25,000. Intech Investment Management LLC bought a new position in Compass Therapeutics in the 3rd quarter worth $30,000. XTX Topco Ltd acquired a new position in Compass Therapeutics during the 3rd quarter worth $37,000. SG Americas Securities LLC boosted its holdings in Compass Therapeutics by 16.6% during the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after acquiring an additional 5,515 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Compass Therapeutics in the second quarter valued at about $41,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.